Mouse models of cancer-associated thrombosis
Cancer patients have 4-7 fold increased risk of venous thromboembolism (VTE) compared with a general population ....
Most Read
The safety of DOACs to treat VTE in patients with brain tumors
Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism (VTE), occurring in 20-30%...
Is apixaban safe for primary VTE prevention in patients with gastrointestinal cancers? A summary of a post-hoc analysis of the AVERT trial
Patients with cancer and a Khorana score ≥2 have an estimated risk of symptomatic venous thromboembolism (VTE) of...
Abstract submission now open for ESMO 2023
Time to submit your abstract for the next European Society for Medical Oncology (ESMO) Congress. The ESMO...
ASCO Guideline Update on VTE Prophylaxis and Treatment in Patients with Cancer
The American Society of Clinical Oncology (ASCO) has been developing guidelines on cancer-associated thrombosis (CAT)...
ASH Scientific Workshop “Interplay between coagulation and malignancy”
The American Society of Hematology (ASH) is the world’s largest professional society serving clinicians and...
Management of VTE beyond 12 months in patients with cancer-associated thrombosis
During the ICTHIC webinar, “Long-term treatment & DDI implications in the management of CAT,” Dr. Luis...
Management of the incidents of VTE in cancer patients
During the ICTHIC webinar, “Updates in cancer-associated thrombosis,” Dr. Luis Jara-Palomares gave a lecture on the...
Looking for a reliable tool to identify hypercoagulant markers for cancer risk and prognosis: the HYPERCAN study
The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...
Cancer-associated thrombosis in the pediatric setting: A chat with Prof. Gili Kenet
Prof. Gili Kenet is a Pediatric Hematologist, Professor and Chair of the Haematology Department at the Sackler Medical...